TCR基因突变分析技术对癌症放疗患者生物剂量估算价值的探讨

Estimation value of TCR gene mutation analytical technique to the biological dose of radiotherapy patients

目的:探讨TCR突变分析技术估算放疗患者生物剂量的可行性。方法:分别取16例不同照射剂量的癌症患者和16例健康对照组的血样,进行细胞培养分析T淋巴细胞受体突变频率(TCRMF)以及染色体双着丝粒体和着丝粒环(双+环),并用已建立的生物剂量-效应曲线估算生物剂量。结果:16例癌症患者放疗前和对照组TCRMF的平均值分别为1.853×10-4和1.735×10-4,两组之间差异无统计学意义,P>0.05;癌症患者放疗后的TCRMF随着照射剂量的增加而增加,呈现一定的剂量效应关系,染色体双+环也随着照射剂量的增加而增加,两者的趋势基本一致。用TCR突变分析技术和染色体畸变分析技术,2种方法估算的肿瘤患者全身等效剂量差异无统计学意义,F=0.419 4,P>0.05。结论:TCR基因突变分析技术可以作为一种方法来估算放疗患者所受遗传损伤效应,但是需要更多的资料来完善。

OBJECTIVE： To explore the feasibility of estimating the biological dose of radiotherapy patients by means of TCR gene mutation analysis. METHOD： Cultivate lymphocytes of 16 cancer patients received different irradiation doses and the control group （16 healthy people） respectively, then analysis TCR mutation frequency（TCRMF） and chromosome dicentric and centric ring （dic＋ r）, and estimate the biological dose through the dose-effect curve which had cultivated. RESULTS： The mean of TCRMF for the patients before radiotherapy and the control group was 1. 853 ×10^-4 and 1. 735×10^-4, respectively, with no statistical difference between them （ P 〉 0.05 ）. But the TCRMF of patient after radiotherapy was increased in a dose-dependent trend. There was no statistical difference（F= 0. 419 4,P〉0. 05） between TCR mutation and chromosomal aberration analytical technique to estimate the whole equivalent dose of cancer patients. CONCLUSION： TCR gene mutation analytical technique can be used as a technology to estimate the genetic injury effect of radiotherapy patients, but need more data to consummate.